MovDisordV3, Main, Exploration, bibRecord, 003842

Mouse diaphragm assay for detection of antibodies against botulinum toxin type B

Identifieur interne : 003842 ( Main/Exploration ); précédent : 003841; suivant : 003843

Mouse diaphragm assay for detection of antibodies against botulinum toxin type B

Auteurs : Dirk Dressler [Allemagne] ; M. Lange [Allemagne] ; Hans Bigalke [Allemagne]

Source :

Movement Disorders [ 0885-3185 ] ; 2005-12.

RBID : ISTEX:9024A63E77257377126A0FC967D49F0520D10BA8

Descripteurs français

Pascal (Inist)
- Animal, Bontoxilysin, Diaphragme, Dépistage, Souris, Système nerveux pathologie, Traitement.

English descriptors

KwdEn :
- Animal, Animals, Anti-Dyskinesia Agents (immunology), Anti-Dyskinesia Agents (therapeutic use), Antibodies (analysis), Biological Assay (methods), Bontoxilysin, Botulinum Toxins (immunology), Botulinum Toxins (therapeutic use), Diaphragm, Diaphragm (drug effects), Diaphragm (immunology), Dose-Response Relationship, Drug, Drug Interactions, Female, Humans, Male, Medical screening, Mice, Middle Aged, Mouse, Nervous system diseases, Time Factors, Torticollis (blood), Torticollis (drug therapy), Torticollis (immunology), Treatment, Treatment Failure, antibodies, botulinum toxin type B, mouse diaphragm assay, therapy failure.
MESH :
- chemical , analysis : Antibodies.
- chemical , immunology : Anti-Dyskinesia Agents, Botulinum Toxins.
- chemical , therapeutic use : Anti-Dyskinesia Agents, Botulinum Toxins.
- blood : Torticollis.
- drug effects : Diaphragm.
- drug therapy : Torticollis.
- immunology : Diaphragm, Torticollis.
- methods : Biological Assay.
- Animals, Dose-Response Relationship, Drug, Drug Interactions, Female, Humans, Male, Mice, Middle Aged, Time Factors, Treatment Failure.

Abstract

With the advent of a commercial preparation of botulinum toxin type B (BT‐B) for treatment of cervical dystonia detection of antibodies against BT‐B (BT‐B‐AB) becomes necessary. For this purpose, we carried out a mouse diaphragm assay (MDA) by continuous measurement of the twitch force of a mouse hemidiaphragm preparation elicited by electric stimulation of its phrenic nerve. After exposing the preparation to BT‐B 3 ng/ml the time to half‐maximal twitch force reduction (paralysis time [PT]) was 69 ± 4 min (n = 25). Addition of sera from patients with antibodies against BT‐A produced a PT of 68 ± 5 min (n = 24), whereas addition of sera from controls with antibodies against tetanus toxoid produced a PT of 67 ± 6 min (n = 30). When defined amounts of BT‐B‐AB were added to the MDA, PT was prolonged. This prolongation was correlated closely to the amount of BT‐B‐AB added, thus producing a calibration curve. The threshold for BT‐B‐AB detection was 0.4 mU/ml. When sera from 7 patients (4 women, 3 men; age 50.6 ± 14.2 years) with cervical dystonia (Toronto Western Spasmodic Torticollis Rating Scale score, 18.9 ± 2.9) and complete secondary failure of BT‐B therapy (NeuroBloc; Elan Pharmaceuticals, Shannon, Ireland; 12,229 ± 2,601 MU/injection series, 1.86 ± 0.69 injection series before complete secondary therapy failure; 100.4 ± 15.8 days between injection series with normal therapeutic effect) were tested, BT‐B‐AB titers of more than 10 mU/ml were found in all of them. The MDA can be used to measure neutralizing BT‐B‐AB titers quantitatively and with adequate sensitivity and specificity. Further studies are necessary to understand the role of intermediate BT‐B‐AB titers in partial BT‐B therapy failure. © 2005 Movement Disorder Society

Url:

https://api.istex.fr/document/9024A63E77257377126A0FC967D49F0520D10BA8/fulltext/pdf

DOI: 10.1002/mds.20625

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Mouse diaphragm assay for detection of antibodies against botulinum toxin type B</title>
<author><name sortKey="Dressler, Dirk" sort="Dressler, Dirk" uniqKey="Dressler D" first="Dirk" last="Dressler">Dirk Dressler</name>
</author>
<author><name sortKey="Lange, M" sort="Lange, M" uniqKey="Lange M" first="M." last="Lange">M. Lange</name>
</author>
<author><name sortKey="Bigalke, Hans" sort="Bigalke, Hans" uniqKey="Bigalke H" first="Hans" last="Bigalke">Hans Bigalke</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:9024A63E77257377126A0FC967D49F0520D10BA8</idno>
<date when="2005" year="2005">2005</date>
<idno type="doi">10.1002/mds.20625</idno>
<idno type="url">https://api.istex.fr/document/9024A63E77257377126A0FC967D49F0520D10BA8/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002942</idno>
<idno type="wicri:Area/Istex/Curation">002942</idno>
<idno type="wicri:Area/Istex/Checkpoint">002250</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Dressler D:mouse:diaphragm:assay</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:16078216</idno>
<idno type="wicri:Area/PubMed/Corpus">002F49</idno>
<idno type="wicri:Area/PubMed/Curation">002F49</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003055</idno>
<idno type="wicri:Area/Ncbi/Merge">001363</idno>
<idno type="wicri:Area/Ncbi/Curation">001363</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001363</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Dressler D:mouse:diaphragm:assay</idno>
<idno type="wicri:Area/Main/Merge">004F27</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:06-0191530</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001C29</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001092</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001D91</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Dressler D:mouse:diaphragm:assay</idno>
<idno type="wicri:Area/Main/Merge">005269</idno>
<idno type="wicri:Area/Main/Curation">003842</idno>
<idno type="wicri:Area/Main/Exploration">003842</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Mouse diaphragm assay for detection of antibodies against botulinum toxin type B</title>
<author><name sortKey="Dressler, Dirk" sort="Dressler, Dirk" uniqKey="Dressler D" first="Dirk" last="Dressler">Dirk Dressler</name>
<affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Neurology, Rostock University, Rostock</wicri:regionArea>
<wicri:noRegion>Rostock</wicri:noRegion>
<wicri:noRegion>Rostock</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lange, M" sort="Lange, M" uniqKey="Lange M" first="M." last="Lange">M. Lange</name>
<affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Institute of Toxicology, Medizinische Hochschule, Hannover</wicri:regionArea>
<placeName><region type="land" nuts="2">Basse-Saxe</region>
<settlement type="city">Hanovre</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bigalke, Hans" sort="Bigalke, Hans" uniqKey="Bigalke H" first="Hans" last="Bigalke">Hans Bigalke</name>
<affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Institute of Toxicology, Medizinische Hochschule, Hannover</wicri:regionArea>
<placeName><region type="land" nuts="2">Basse-Saxe</region>
<settlement type="city">Hanovre</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2005-12">2005-12</date>
<biblScope unit="vol">20</biblScope>
<biblScope unit="issue">12</biblScope>
<biblScope unit="page" from="1617">1617</biblScope>
<biblScope unit="page" to="1619">1619</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">9024A63E77257377126A0FC967D49F0520D10BA8</idno>
<idno type="DOI">10.1002/mds.20625</idno>
<idno type="ArticleID">MDS20625</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animal</term>
<term>Animals</term>
<term>Anti-Dyskinesia Agents (immunology)</term>
<term>Anti-Dyskinesia Agents (therapeutic use)</term>
<term>Antibodies (analysis)</term>
<term>Biological Assay (methods)</term>
<term>Bontoxilysin</term>
<term>Botulinum Toxins (immunology)</term>
<term>Botulinum Toxins (therapeutic use)</term>
<term>Diaphragm</term>
<term>Diaphragm (drug effects)</term>
<term>Diaphragm (immunology)</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug Interactions</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Medical screening</term>
<term>Mice</term>
<term>Middle Aged</term>
<term>Mouse</term>
<term>Nervous system diseases</term>
<term>Time Factors</term>
<term>Torticollis (blood)</term>
<term>Torticollis (drug therapy)</term>
<term>Torticollis (immunology)</term>
<term>Treatment</term>
<term>Treatment Failure</term>
<term>antibodies</term>
<term>botulinum toxin type B</term>
<term>mouse diaphragm assay</term>
<term>therapy failure</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Antibodies</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Anti-Dyskinesia Agents</term>
<term>Botulinum Toxins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Dyskinesia Agents</term>
<term>Botulinum Toxins</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Torticollis</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Diaphragm</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Torticollis</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Diaphragm</term>
<term>Torticollis</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Biological Assay</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug Interactions</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Mice</term>
<term>Middle Aged</term>
<term>Time Factors</term>
<term>Treatment Failure</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Animal</term>
<term>Bontoxilysin</term>
<term>Diaphragme</term>
<term>Dépistage</term>
<term>Souris</term>
<term>Système nerveux pathologie</term>
<term>Traitement</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">With the advent of a commercial preparation of botulinum toxin type B (BT‐B) for treatment of cervical dystonia detection of antibodies against BT‐B (BT‐B‐AB) becomes necessary. For this purpose, we carried out a mouse diaphragm assay (MDA) by continuous measurement of the twitch force of a mouse hemidiaphragm preparation elicited by electric stimulation of its phrenic nerve. After exposing the preparation to BT‐B 3 ng/ml the time to half‐maximal twitch force reduction (paralysis time [PT]) was 69 ± 4 min (n = 25). Addition of sera from patients with antibodies against BT‐A produced a PT of 68 ± 5 min (n = 24), whereas addition of sera from controls with antibodies against tetanus toxoid produced a PT of 67 ± 6 min (n = 30). When defined amounts of BT‐B‐AB were added to the MDA, PT was prolonged. This prolongation was correlated closely to the amount of BT‐B‐AB added, thus producing a calibration curve. The threshold for BT‐B‐AB detection was 0.4 mU/ml. When sera from 7 patients (4 women, 3 men; age 50.6 ± 14.2 years) with cervical dystonia (Toronto Western Spasmodic Torticollis Rating Scale score, 18.9 ± 2.9) and complete secondary failure of BT‐B therapy (NeuroBloc; Elan Pharmaceuticals, Shannon, Ireland; 12,229 ± 2,601 MU/injection series, 1.86 ± 0.69 injection series before complete secondary therapy failure; 100.4 ± 15.8 days between injection series with normal therapeutic effect) were tested, BT‐B‐AB titers of more than 10 mU/ml were found in all of them. The MDA can be used to measure neutralizing BT‐B‐AB titers quantitatively and with adequate sensitivity and specificity. Further studies are necessary to understand the role of intermediate BT‐B‐AB titers in partial BT‐B therapy failure. © 2005 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Allemagne</li>
</country>
<region><li>Basse-Saxe</li>
</region>
<settlement><li>Hanovre</li>
</settlement>
</list>
<tree><country name="Allemagne"><noRegion><name sortKey="Dressler, Dirk" sort="Dressler, Dirk" uniqKey="Dressler D" first="Dirk" last="Dressler">Dirk Dressler</name>
</noRegion>
<name sortKey="Bigalke, Hans" sort="Bigalke, Hans" uniqKey="Bigalke H" first="Hans" last="Bigalke">Hans Bigalke</name>
<name sortKey="Lange, M" sort="Lange, M" uniqKey="Lange M" first="M." last="Lange">M. Lange</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003842 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003842 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:9024A63E77257377126A0FC967D49F0520D10BA8
   |texte=   Mouse diaphragm assay for detection of antibodies against botulinum toxin type B
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Mouse diaphragm assay for detection of antibodies against botulinum toxin type B

Mouse diaphragm assay for detection of antibodies against botulinum toxin type B

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.